Clover Health Investments Corp. Cl A (CLOV): Price and Financial Metrics
GET POWR RATINGS... FREE!
CLOV Stock Price Chart Interactive Chart >
CLOV Price/Volume Stats
| Current price | $12.04 | 52-week high | $28.85 |
| Prev. close | $12.56 | 52-week low | $6.31 |
| Day low | $12.02 | Volume | 34,165,200 |
| Day high | $13.45 | Avg. volume | 35,102,188 |
| 50-day MA | $9.52 | Dividend yield | N/A |
| 200-day MA | $10.76 | Market Cap | 4.91B |
Clover Health Investments Corp. Cl A (CLOV) Company Bio
Clover Health Investments, Corp. provides health insurance services. The company was founded in 2012 and is based in Franklin, Tennessee.
Latest CLOV News From Around the Web
Below are the latest news stories about Clover Health Investments Corp that investors may wish to consider to help them evaluate CLOV as an investment opportunity.
'In the streaming world, local television simply doesn’t exist': CEO of MNTNMark Douglas, CEO of MNTN, joined Yahoo Finance Live to break down the outlook on the media industry. |
Influencers with Andy Serwer: David RicksIn this episode of Influencers, Eli Lilly Chairman & CEO David Ricks joins Andy to discuss the latest in the pharmaceutical industry, new progress in the fight against COVID-19, and potential groundbreaking advancements for the treatment of Alzheimer’s. |
By next summer we'll have enough vaccines to vaccinate the world: Eli Lilly CEOEli Lilly CEO David Ricks joins 'Influencers with Andy Serwer' to discuss progress in the fight against COVID-19. |
Replay: “SPAC to the Future 2” with Gallagher, Stifel, Nasdaq, ICR, MorganFranklin, V&E Featuring Hennessy, Bespoke, SOACIf 2020 was the “Year of the SPAC,” 2021 might become known as “The SPAC Pullback.” Despite some recent signs of renewed investor interest, SPAC preparedness in the current environment is more important than ever, along with strategies for managing D&O and other insurance costs. Pre-revenue companies in particular going public via SPAC face greater […] |
FDA ‘shifting the bar’ for approval with new Alzheimer’s drug: Eli Lilly CEOEli Lilly CEO David Ricks joins 'Influencers with Andy Serwer' to discuss the FDA's approval of Biogen's new Alzheimer’s drug. |
CLOV Price Returns
| 1-mo | 73.74% |
| 3-mo | 36.97% |
| 6-mo | -10.48% |
| 1-year | 13.58% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -28.21% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...